- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02632071
ACY-1215 + Nab-paclitaxel in Metastatic Breast Cancer
Multi-center Phase IB Trial of ACY-1215 (Ricolinostat) Combined With Nab-paclitaxel in Unresectable or Metastatic Breast Cancer
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Study Type
Enrollment (Actual)
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
New York
-
New York, New York, United States, 10032
- Columbia Irving University Medical Center
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Subjects have histologically confirmed adenocarcinoma of the breast -- all breast cancer subtypes are allowed.
- Unresectable or metastatic breast cancer. Locally recurrent disease must not be amenable to any local treatment with curative intent. Metastatic disease must be demonstrated either radiographically or histologically.
- Patients may have measurable disease only, non-measurable disease only, or both (RECIST 1.1).
- ECOG performance status of 0-1.
- Must have recovered from the acute toxic effects of all prior therapy prior to registration for this study to grade 1 or less.
- Women and men of all races and ethnic groups are eligible for this trial.
Minimum number of prior treatments required given standard nab-paclitaxel dosing:
- If HER2 negative: none
- If HER2 positive: two prior regimens containing HER2 targeted therapies in the inoperable locally advanced and/or metastatic setting. Prior therapy for inoperable locally advanced/metastatic disease should include trastuzumab plus pertuzumab as well as ado-trastuzumab. Pertuzumab and ado-trastuzumab must have been previously used, unless for reasons that include, but are not limited, to the following: intolerance to pertuzumab and/or ado-trastuzumab, medical contraindication, regimen declined by patient, treating investigator discretion, or medical insurance coverage issues which prevented administration of pertuzumab or ado-trastuzumab. These reasons must be reviewed with the study chairs and documented in the medical record and care report form. Patients who relapse within 12 months of completing neoadjuvant/adjuvant pertuzumab or ado-trastuzumab would be considered as having progressed on that regimen.
There is no maximum number of prior treatments allowed in the metastatic setting.
- Age >18 years. Because breast carcinoma is a disease of adults that rarely occurs in children, children are excluded from this study.
Patients must have normal organ and marrow function as defined below:
- leukocytes ≥3,000/mcL
- absolute neutrophil count ≥1,500/mcL
- platelets ≥100,000/mcL
- hemoglobin ≥9 g/dL
- total bilirubin ≤ 1.5 × the upper limit of normal
- AST(SGOT)/ALT(SGPT) ≤2.5 × institutional upper limit of normal
- Serum creatinine ≤ 1.5 × the upper limit of normal or calculated creatinine clearance ≥ 60 mL/min
- Subject is capable of understanding the informed consent process.
- The effects of ACY-1215 on the developing human fetus are unknown. For this reason and because the effects of chemotherapy are known to be teratogenic, women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation. Should a woman become pregnant or suspect she is pregnant while she or her partner is participating in this study, she should inform her treating physician immediately. Men treated or enrolled on this protocol must also agree to use adequate contraception prior to the study, for the duration of study participation, and 2 weeks after completion of ACY-1215 administration.
Exclusion Criteria:
- Patients who have had chemotherapy, hormonal therapy, or radiotherapy within 2 weeks prior to entering the study or those who have not recovered from adverse events due to agents administered more than 2 weeks earlier. Concomitant treatment with bone-targeted therapies such as RANKL inhibitors or bisphosphonates is allowed.
- Patients who are receiving any other investigational agents concurrently or have received investigational agents within 2 weeks or 5 half-lives of the compound or active metabolites, whichever is longer before the first dose of the study treatment.
- Patients who have received HDAC inhibitors (including valproic acid, entinostat, vorinostat) are excluded
- Subject is pregnant or nursing. Pregnant women are excluded from this study because ACY-1215 is an investigational therapy with unknown potential for teratogenic or abortifacient effects. Because there is an unknown but potential risk for adverse events in nursing infants secondary to treatment of the mother with ACY-1215, breastfeeding should be discontinued if the mother is treated with ACY-1215.
- Symptomatic or unstable brain metastases. (Note: Asymptomatic patients with metastatic brain disease who have been on a stable dose of corticosteroids for treatment of brain metastases for at least 14 days prior to registration are eligible to participate in the study).
- HIV+ with a CD4 count <200 are ineligible because these patients are at increased risk of lethal infections when treated with marrow-suppressive therapy. Appropriate studies will be undertaken in patients receiving combination antiretroviral therapy when indicated.
- Patients receiving any medications or substances that are strong inhibitors of CYP450 3A4 isoenzyme.
- History of allergic reactions attributed to compounds of similar chemical or biologic composition to nab-paclitaxel.
- Uncontrolled intercurrent illness including but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements.
- Corrected QT interval (QTc) value > 480 msec at screening; family or personal history of long QTc syndrome or ventricular arrhythmias including ventricular bigeminy at screening; previous history of drug-induced QTc prolongation or the need for treatment with medications known or suspected of producing prolonged QTc intervals on electrocardiogram (EKG). If QTc prolongation on screening ECG is felt to be related to electrolyte imbalance, an EKG can be repeated after correction of electrolytes.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: 80 mg
Subject will receive ACY-1215 (ricolinostat) orally once daily for 21 consecutive days (Day 1 to Day 21) at the assigned dose, followed by a 7-day non-dosing period (Day 22 to Day 28). 100 mg/m2 Nab-paclitaxel will be administered intravenously on Days 1, 8, and 15.
|
An orally active, selective HDAC6 inhibitor.
Assigned dosing 80 mg, 120 mg, 180 mg, 240 mg PO, once daily Days 1-21 in a 28-day cycle
Other Names:
Taxanes are among the most widely used chemotherapy agents in the treatment of breast cancer. 100 mg/m2 30 minute IV infusion Days 1, 8, and 15 in a 28-day cycle
Other Names:
|
Active Comparator: 120 mg
Subject will receive ACY-1215 (ricolinostat) orally once daily for 21 consecutive days (Day 1 to Day 21) at the assigned dose, followed by a 7-day non-dosing period (Day 22 to Day 28). 100 mg/m2 Nab-paclitaxel will be administered intravenously on Days 1, 8, and 15.
|
An orally active, selective HDAC6 inhibitor.
Assigned dosing 80 mg, 120 mg, 180 mg, 240 mg PO, once daily Days 1-21 in a 28-day cycle
Other Names:
Taxanes are among the most widely used chemotherapy agents in the treatment of breast cancer. 100 mg/m2 30 minute IV infusion Days 1, 8, and 15 in a 28-day cycle
Other Names:
|
Active Comparator: 180 mg
Subject will receive ACY-1215 (ricolinostat) orally once daily for 21 consecutive days (Day 1 to Day 21) at the assigned dose, followed by a 7-day non-dosing period (Day 22 to Day 28). 100 mg/m2 Nab-paclitaxel will be administered intravenously on Days 1, 8, and 15.
|
An orally active, selective HDAC6 inhibitor.
Assigned dosing 80 mg, 120 mg, 180 mg, 240 mg PO, once daily Days 1-21 in a 28-day cycle
Other Names:
Taxanes are among the most widely used chemotherapy agents in the treatment of breast cancer. 100 mg/m2 30 minute IV infusion Days 1, 8, and 15 in a 28-day cycle
Other Names:
|
Active Comparator: 240 mg
Subject will receive ACY-1215 (ricolinostat) orally once daily for 21 consecutive days (Day 1 to Day 21) at the assigned dose, followed by a 7-day non-dosing period (Day 22 to Day 28). 100 mg/m2 Nab-paclitaxel will be administered intravenously on Days 1, 8, and 15.
|
An orally active, selective HDAC6 inhibitor.
Assigned dosing 80 mg, 120 mg, 180 mg, 240 mg PO, once daily Days 1-21 in a 28-day cycle
Other Names:
Taxanes are among the most widely used chemotherapy agents in the treatment of breast cancer. 100 mg/m2 30 minute IV infusion Days 1, 8, and 15 in a 28-day cycle
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Maximum tolerated dose (MTD) of ACY-1215 (Ricolinostat)
Time Frame: 28 days
|
The maximum tolerated dose (MTD) combination is defined as the dose combination associated with a target probability of dose limiting toxicity (DLT) of 0.25.
A dose-limiting toxicity is defined as the MTD with DLTs defined as any grade 3 non-hematologic toxicities despite maximal supportive care or any grade 4 hematologic toxicity.
The MTD will be estimated using the time to event continual reassessment method (TITE-CRM).
The TITE-CRM will use an empirical dose-toxicity model, with a sample size of 24.
The dose-toxicity model is calibrated such that the method will eventually select a dose that yields between 17% and 33% DLT, which will be the recommended phase II dose (RP2D).
|
28 days
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of adverse events related to ACY-1215 (Ricolinostat)
Time Frame: up to 14 days following the last administration of study treatment
|
All patients will be evaluable for toxicity from the time of their first treatment with the study drug.
Toxicities will be graded based upon CTCAE v4.0.2.
|
up to 14 days following the last administration of study treatment
|
Collaborators and Investigators
Sponsor
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Skin Diseases
- Neoplasms
- Neoplasms by Site
- Breast Diseases
- Breast Neoplasms
- Molecular Mechanisms of Pharmacological Action
- Enzyme Inhibitors
- Antineoplastic Agents
- Tubulin Modulators
- Antimitotic Agents
- Mitosis Modulators
- Antineoplastic Agents, Phytogenic
- Histone Deacetylase Inhibitors
- Paclitaxel
- Ricolinostat
Other Study ID Numbers
- AAAQ3709
- 5U01CA168426 (U.S. NIH Grant/Contract)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Metastatic Breast Cancer
-
Gilead SciencesRecruitingStudy of Sacituzumab Govitecan (SG) in Japanese Participants With Advanced Solid Tumors (ASCENT-J02)Advanced Solid Tumor | Metastatic Urothelial Cancer | Metastatic Triple-Negative Breast Cancer | HR+/HER2- Metastatic Breast CancerJapan
-
BriaCell Therapeutics CorporationRecruitingBreast Cancer | Breast Neoplasm | Metastatic Breast Cancer | Breast Cancer Metastatic | End Stage CancerUnited States
-
GlycoMimetics IncorporatedTerminatedBreast Cancer | Breast Cancer Metastatic | HR+ Metastatic Breast CancerUnited States
-
OBI Pharma, IncCompletedMetastatic Colorectal Cancer | Metastatic Lung Cancer | Metastatic Breast Cancer | Metastatic Gastric CancerTaiwan
-
Massachusetts General HospitalPuma Biotechnology, Inc.; Celcuity, Inc.WithdrawnMetastatic Breast Cancer | Invasive Breast Cancer | HER2-negative Breast Cancer | ER Positive Breast Cancer | PR-Positive Breast Cancer | Stage IV (Metastatic) Breast CancerUnited States
-
BriaCell Therapeutics CorporationLumaBridgeEnrolling by invitationBreast Cancer | Breast Neoplasm | Metastatic Breast Cancer | Breast Cancer MetastaticUnited States
-
Institut de Recherches Internationales ServierADIR, a Servier Group companyCompletedMetastatic Breast Cancer | Metastatic Triple Negative Breast CancerJapan, Belgium, France, Netherlands
-
Novartis PharmaceuticalsCompletedMetastatic Breast Cancer | Postmenopausal Women | Locally Advanced Metastatic Breast CancerIsrael
-
Hoffmann-La RocheCompletedHER2-Positive Metastatic Breast Cancer | HER2-Negative Metastatic Breast Cancer | Locally Advanced or Early Breast CancerUnited States
-
Prof. Wolfgang JanniEli Lilly and CompanyRecruitingHormone Receptor-positive Metastatic Breast Cancer | HER2-negative Metastatic Breast CancerGermany, Switzerland
Clinical Trials on ACY-1215
-
Jennifer AmengualAcetylon Pharmaceuticals IncorporatedCompletedLymphoma | Lymphoid MalignanciesUnited States
-
Acetylon Pharmaceuticals IncorporatedCompletedHealthyUnited States
-
Regenacy Pharmaceuticals LLCCompletedPainful Diabetic Peripheral NeuropathyUnited States
-
Dana-Farber Cancer InstituteAcetylon Pharmaceuticals IncorporatedActive, not recruitingRecurrent Chronic Lymphoid LeukemiaUnited States
-
CelgeneThe Leukemia and Lymphoma SocietyCompletedMultiple MyelomaUnited States
-
CelgeneCompleted
-
National Institute of Allergy and Infectious Diseases...Moderna TX, IncActive, not recruiting
-
CelgeneCompletedAdvanced Solid TumorsUnited States
-
Dana-Farber Cancer InstituteCelgene CorporationTerminatedOvarian Cancer | Fallopian Tube Cancer | Primary Peritoneal CarcinomaUnited States
-
CelgeneActive, not recruitingNon Small Cell Lung CancerUnited States